More Videos
SPECIAL REPORT
MOST SHARED
- Future of Marketing
- Oil Tomorrow
- Priceline Crushes Profit Forecasts; Shares Jump
- Home Prices Start to Stabilize In the US as Sales Pick Up
- Dow Industrials at New Highs—But Other Indices Lag
- Dow Up Over 100 After G20 Stimulus Pledge
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- 'Modern Warfare 2': Biggest Entertainment Event of 2009?
- Sprint to Cut Up to 2,500 Jobs, Sees Charge
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- Modern Warfare 2's Record-Breaking Launch
- Merck’s Mega-Monday Morning
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- S&P Stocks Trading at New 52-Week Highs
- Shopping for Answers
- Obama Says Will Raise Currency Issue with China
- Look Ahead: 'Risk On' Attitude Could Fuel Rally Further
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Buffett to Sell Stakes in Norfolk Southern, Union Pacific
- Cramer: 5 Stocks to Play the Next Bull Run
- Do You Know Your Coca-Cola Myths?
- Electronic Arts Beats Street, Announces 1,500 Job Cuts
- Time Is Here to Look at Overseas Stocks: Bill Gross
- Home Prices Start to Stabilize In the US as Sales Pick Up
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
] and Schering-Plough [SGP
Loading...
()
] announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.Analysts didn't have high hopes for the drug (especially after the agency recently revealed it's investigating a possible association between Singulair and suicidal behavior), so investors seem to be shrugging off the news.
In fact, MRK shares are rallying this morning ahead of an anticipated FDA decision sometime today on its cholesterol drug called Cordaptive. It's a combo of Niacin and a special ingredient to reduce the facial flushing side effects of Niacin. Analyst estimates for peak sales of Cordaptive range from a few hundred million bucks a year to billion-dollar blockbuster status.
Abbott Labs [ABT
Loading...
()
] makes a Niacin drug called Niaspan which could possibly take a hit if/when Cordaptive gets approved. Today is the date given as the PDUFA (Prescription Drug User Fee Act) or what, in plain English, I like to call the"action day" for an FDA Cordaptive decision in case you're wondering how people know when this kind of stuff is gonna happen.
Also late Friday, Bristol-Myers Squibb [BMY
Loading...
()
] and Medarex [MEDX
Loading...
()
] announced a regulatory delay for their skin cancer treatment. MEDX shares hit a new intra-day low earlier this morning. The FDA wants the companies to test and see if the drug helps people live longer rather than just extending the amount of time that goes by before the cancer worstens.
Meantime, after dueling data presentations at a scientific conference in Milan over the weekend, analysts are declaring Vertex Pharmaceuticals [VRTX
Loading...
()
] the winner versus Schering-Plough in the latest round of the Hepatitis C drug battle. Vertex is partnered with Johnson and Johnson [JNJ
Loading...
()
] on telaprevir. Wachovia's George Farmer calls SGP's data "underwhelming" and says VRTX's data "positions telaprevir as the (Hepatitis C drug) of choice between these two candidates." Leerink Swann's Howard Liang says Schering's drug is "in the game" but adds, "Advantage goes to telaprevir."
Hep C doesn't get much mainstream media play, but in medical and investment circles it is considered to be a big area of unmet need and a potential goldmine for drug companies that can develop better treatments. The drugs on the market today don't work on many patients and can make them feel like they have the flu. VRTX and SGP have the most mature pipeline products, but other companies are also in various earlier stages of developing Hep C drugs.
Wachovia and Leerink Swann make a market in VRTX and LS trades in SGP.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes